InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or ...
C4 Therapeutics has begun dosing in a Phase Ib study assessing cemsidomide and elranatamab (Elrexfio) in patients with ...
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple ...
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 ...
Research published in Clinical Lymphoma, Myeloma and Leukemia identifies Kappa Myeloma Antigen and Lambda Myeloma Antigen as ...
Topical immunotherapy remains an effective, affordable option for alopecia areata, with long-term control seen in multimodal treatment approaches. Topical immunotherapy continues to have a significant ...
With optimal treatment, myeloma isn't immediately life-threatening. Many patients live for years after their diagnosis, often ...
Natalia Neparidze, MD, discusses subcutaneous daratumumab safety, MRD as a clinical endpoint, and emerging therapies for ...
11h
Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond
Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack tumors. They work for ...
Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
The global epidemiology and prognosis of meningitis have been transformed by the introduction of conjugate vaccines, and by advances in antimicrobial therapy, critical care, and adjunctive treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results